View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNutraLife BioSciences 配当と自社株買い配当金 基準チェック /06NutraLife BioSciences配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Nov 15NutraLife BioSciences, Inc. announced delayed 10-Q filingOn 11/14/2022, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 16NutraLife BioSciences, Inc. announced delayed 10-Q filingOn 08/15/2022, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17NutraLife BioSciences, Inc. announced delayed 10-Q filingOn 05/16/2022, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 31NutraLife BioSciences, Inc. announced delayed annual 10-K filingOn 03/30/2022, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Apr 02NutraLife BioSciences, Inc. announced delayed annual 10-K filingOn 03/31/2021, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 20NutraLife BioSciences, Inc. Finalizes Product Registration With The U.S. FDANutraLife BioSciences, Inc. announced that it received its product registration number from the Food and Drug Administration (FDA) and has completed its first production run of Oral Shield antiseptic protection mouth spray. The company recently received an initial purchase order to manufacture 25,000 units of which 12,500 are planned to be exported to Indonesia and 12,500 for domestic distribution. The Company has since received a second order to produce 87,500 units, as the Company enters the new product launch phase. The company along with its partners plans to market and distribute the product on a global scale and seeks to provide a convenient, travel-size, quality, multi-functioning antiseptic mouth spray for consumers to use throughout the day.お知らせ • Nov 06NutraLife BioSciences, Inc. Signs Multi-Year Manufacturing, Distribution and Sales Agreement with 27Health Inc. for the Launch of Covi-Guard™ Oral SanitizerNutraLife BioSciences, Inc. to announce that it has entered into a multi-year Manufacturing, Distribution and Sales Agreement with 27Health Inc. for the launch of 27Health’s Covi-Guard Oral Sanitizer. Simultaneously, NutraLife, Lord Global, and 27Health also entered into a Stock Purchase Agreement pursuant to which NutraLife acquired shares of Lord Global preferred stock convertible into approximately 15.7% of Lord Global’s issued and outstanding common stock, subject to a 4.99% equity blocker, and 27Health acquired 12,500,000 shares of NutraLife common stock, representing approximately 7.9% of NutraLife’s issued and outstanding common stock. 27Health is the exclusive marketer and producer of the Covi-Guard family of oral sanitizers. Covi-Guard is a patent-pending oral mouthwash and spray which may dramatically help to lower the viral and bacterial load in the oral cavity. According to a recent Penn State University study published in the Journal of Medical Virology, certain mouthwashes and oral rinses may ‘inactivate’ coronaviruses. Covi-Guard’s several active ingredients individually and in combination destroy the lipid envelope of viruses, including coronaviruses. This combats virus replication in the mouth and throat and 27Health believes the product may help disrupt the transmission of coronaviruses. Covi-Guard has not been proven to prevent, or cure, COVID-19, and does not replace the need for masks and social distancing. All of the ingredients are currently used, especially in dental offices, and the product line will carry an FDA OTC moniker. Pursuant to the Manufacturing, Distribution, and Sales Agreement, NutraLife will act as 27Health’s primary Covi-Guard manufacturer. If demand is greater than NutraLife’s significant capacity (initially 30,000 units/day), 27Health may use other manufacturers. In addition to being 27Health’s primary manufacturer, NutraLife will also be a non-exclusive wholesaler, agent, and fulfillment center for the Covi-Guard family of products. NutraLife believes that this will enable NutraLife to significantly increase its operating margins by acting in multiple roles.お知らせ • Sep 04NutraLife BioSciences, Inc. announced a financing transactionNutraLife BioSciences, Inc. (OTCPK:NLBS) announced a private placement of shares for gross proceeds of $500,200 on August 14, 2020. The company will issue common shares in the transaction pursuant to exemption provided under regulation D.決済の安定と成長配当データの取得安定した配当: NLBSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: NLBSの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場NutraLife BioSciences 配当利回り対市場NLBS 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NLBS)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Personal Products)3.2%アナリスト予想 (NLBS) (最長3年)n/a注目すべき配当: NLBSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: NLBSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: NLBSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: NLBSが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/12/05 09:10終値2024/10/17 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NutraLife BioSciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 15NutraLife BioSciences, Inc. announced delayed 10-Q filingOn 11/14/2022, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 16NutraLife BioSciences, Inc. announced delayed 10-Q filingOn 08/15/2022, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17NutraLife BioSciences, Inc. announced delayed 10-Q filingOn 05/16/2022, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 31NutraLife BioSciences, Inc. announced delayed annual 10-K filingOn 03/30/2022, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Apr 02NutraLife BioSciences, Inc. announced delayed annual 10-K filingOn 03/31/2021, NutraLife BioSciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 20NutraLife BioSciences, Inc. Finalizes Product Registration With The U.S. FDANutraLife BioSciences, Inc. announced that it received its product registration number from the Food and Drug Administration (FDA) and has completed its first production run of Oral Shield antiseptic protection mouth spray. The company recently received an initial purchase order to manufacture 25,000 units of which 12,500 are planned to be exported to Indonesia and 12,500 for domestic distribution. The Company has since received a second order to produce 87,500 units, as the Company enters the new product launch phase. The company along with its partners plans to market and distribute the product on a global scale and seeks to provide a convenient, travel-size, quality, multi-functioning antiseptic mouth spray for consumers to use throughout the day.
お知らせ • Nov 06NutraLife BioSciences, Inc. Signs Multi-Year Manufacturing, Distribution and Sales Agreement with 27Health Inc. for the Launch of Covi-Guard™ Oral SanitizerNutraLife BioSciences, Inc. to announce that it has entered into a multi-year Manufacturing, Distribution and Sales Agreement with 27Health Inc. for the launch of 27Health’s Covi-Guard Oral Sanitizer. Simultaneously, NutraLife, Lord Global, and 27Health also entered into a Stock Purchase Agreement pursuant to which NutraLife acquired shares of Lord Global preferred stock convertible into approximately 15.7% of Lord Global’s issued and outstanding common stock, subject to a 4.99% equity blocker, and 27Health acquired 12,500,000 shares of NutraLife common stock, representing approximately 7.9% of NutraLife’s issued and outstanding common stock. 27Health is the exclusive marketer and producer of the Covi-Guard family of oral sanitizers. Covi-Guard is a patent-pending oral mouthwash and spray which may dramatically help to lower the viral and bacterial load in the oral cavity. According to a recent Penn State University study published in the Journal of Medical Virology, certain mouthwashes and oral rinses may ‘inactivate’ coronaviruses. Covi-Guard’s several active ingredients individually and in combination destroy the lipid envelope of viruses, including coronaviruses. This combats virus replication in the mouth and throat and 27Health believes the product may help disrupt the transmission of coronaviruses. Covi-Guard has not been proven to prevent, or cure, COVID-19, and does not replace the need for masks and social distancing. All of the ingredients are currently used, especially in dental offices, and the product line will carry an FDA OTC moniker. Pursuant to the Manufacturing, Distribution, and Sales Agreement, NutraLife will act as 27Health’s primary Covi-Guard manufacturer. If demand is greater than NutraLife’s significant capacity (initially 30,000 units/day), 27Health may use other manufacturers. In addition to being 27Health’s primary manufacturer, NutraLife will also be a non-exclusive wholesaler, agent, and fulfillment center for the Covi-Guard family of products. NutraLife believes that this will enable NutraLife to significantly increase its operating margins by acting in multiple roles.
お知らせ • Sep 04NutraLife BioSciences, Inc. announced a financing transactionNutraLife BioSciences, Inc. (OTCPK:NLBS) announced a private placement of shares for gross proceeds of $500,200 on August 14, 2020. The company will issue common shares in the transaction pursuant to exemption provided under regulation D.